ABP 234 (pembrolizumab biosimilar) / Amgen - LARVOL DELTA

Eucalyptus: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (clinicaltrials.gov) - P3 | N=154 | Recruiting | Sponsor: Amgen | Trial completion date: Mar 2027 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=927 | Recruiting | Sponsor: Amgen | Trial completion date: Oct 2027 ➔ May 2028 | Trial primary completion date: Oct 2027 ➔ Feb 2028

Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Eucalyptus: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (clinicaltrials.gov) - P3 | N=154 | Recruiting | Sponsor: Amgen | Trial completion date: Oct 2026 ➔ Feb 2027 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=927 | Recruiting | Sponsor: Amgen | Trial completion date: Jun 2026 ➔ Oct 2027 | Trial primary completion date: Jun 2026 ➔ Oct 2027

Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=927 | Recruiting | Sponsor: Amgen | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Eucalyptus: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (clinicaltrials.gov) - P3 | N=154 | Recruiting | Sponsor: Amgen | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Eucalyptus: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (clinicaltrials.gov) - P3 | N=154 | Not yet recruiting | Sponsor: Amgen | Initiation date: Jul 2024 ➔ Oct 2024

Trial initiation date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=927 | Not yet recruiting | Sponsor: Amgen | Trial completion date: Oct 2027 ➔ Jun 2026 | Trial primary completion date: Oct 2027 ➔ Jun 2026

Metastases • Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Eucalyptus: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (clinicaltrials.gov) - P3 | N=154 | Not yet recruiting | Sponsor: Amgen

New P3 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=927 | Not yet recruiting | Sponsor: Amgen

Metastases • New P3 trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor